HER2 LOW BREAST CARCINOMA
Clinical trials for HER2 LOW BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2 LOW BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2 LOW BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Smart Bomb' drug targets Tough-to-Treat breast cancer
Disease control Not yet recruitingThis study is testing a new drug called ARX788 for people with advanced HER2-low breast cancer that has spread or cannot be removed by surgery. ARX788 is an antibody-drug conjugate, which works like a 'smart bomb'—it attaches to cancer cells and delivers a toxin to kill them. The…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for Tough-to-Treat breast cancer: testing a powerful drug duo
Disease control Not yet recruitingThis study is testing whether combining two drugs, elacestrant and trastuzumab deruxtecan, can help control advanced breast cancer that has grown despite prior hormone-based therapies. It will involve about 65 people with specific types of breast cancer (HR+/HER2-low or ultralow)…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sarah Sammons, MD • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC